Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BHC 
Bausch Health Companies Inc (BHC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/10/2025: BHC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.17
1 Year Target Price $7.17
| 0 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.87% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/10/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.46B USD | Price to earnings Ratio 6.86 | 1Y Target Price 7.17 |
Price to earnings Ratio 6.86 | 1Y Target Price 7.17 | ||
Volume (30-day avg) 7 | Beta 0.4 | 52 Weeks Range 4.25 - 9.31 | Updated Date 11/9/2025 |
52 Weeks Range 4.25 - 9.31 | Updated Date 11/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-29 | When - | Estimate 1.04 | Actual 1.1638 |
Profitability
Profit Margin 3.61% | Operating Margin (TTM) 26.74% |
Management Effectiveness
Return on Assets (TTM) 4.83% | Return on Equity (TTM) 56.32% |
Valuation
Trailing PE 6.86 | Forward PE 1.58 | Enterprise Value 22440763128 | Price to Sales(TTM) 0.25 |
Enterprise Value 22440763128 | Price to Sales(TTM) 0.25 | ||
Enterprise Value to Revenue 2.28 | Enterprise Value to EBITDA 7.48 | Shares Outstanding 370516926 | Shares Floating 226348790 |
Shares Outstanding 370516926 | Shares Floating 226348790 | ||
Percent Insiders 10.76 | Percent Institutions 67.41 |
Upturn AI SWOT
Bausch Health Companies Inc
Company Overview
History and Background
Bausch Health Companies Inc. (BHC) was founded in 1853 as Bausch & Lomb, initially focusing on ophthalmic products. Over time, it expanded through acquisitions and strategic shifts, eventually changing its name to Valeant Pharmaceuticals. Following significant debt accumulation and controversies, the company rebranded as Bausch Health in 2018 to signify a fresh start.
Core Business Areas
- Bausch + Lomb: Focuses on vision care products, including contact lenses, lens care solutions, over-the-counter ophthalmic medications, and ophthalmic surgical devices and instruments.
- Salix Pharmaceuticals: Dedicated to gastrointestinal (GI) health. Their products treat conditions such as irritable bowel syndrome (IBS), hepatic encephalopathy, and other GI disorders.
- International Rx: Markets a range of prescription drugs in various therapeutic areas outside the United States and Canada.
Leadership and Structure
The current CEO is Thomas Appio. The company has a board of directors responsible for oversight and strategic direction. The organizational structure is divided by business segments (Bausch + Lomb, Salix, International) and functional areas (R&D, Finance, Operations).
Top Products and Market Share
Key Offerings
- XIFAXAN (rifaximin): A treatment for irritable bowel syndrome with diarrhea (IBS-D) and hepatic encephalopathy (HE). Competitors include other IBS-D treatments and HE management therapies. Salix, a Bausch Health company, has a significant market share in rifaximin-based treatments.
- Lotemax: A steroid eye drop used to treat inflammation and pain after eye surgery. Competitors include other topical ophthalmic corticosteroids. Bausch + Lomb holds a portion of the topical ophthalmic steroid market.
- Bausch + Lomb ULTRA: A family of contact lenses for daily, extended and multifocal use. Major players in this industry are Alcon (ALC), Johnson & Johnson (JNJ), and CooperVision (COO).
Market Dynamics
Industry Overview
The pharmaceutical and vision care industries are characterized by intense competition, regulatory scrutiny, patent protection, and evolving consumer preferences. Innovation and strategic partnerships are key to success.
Positioning
Bausch Health is positioned as a diversified healthcare company with a strong presence in vision care and gastrointestinal health. Its competitive advantages include a broad product portfolio and established brand recognition. However, its high debt levels and past controversies remain challenges.
Total Addressable Market (TAM)
The global vision care and gastroenterology markets are substantial, estimated to be in the tens of billions of dollars annually. Bausch Health is positioned to capture a share of these markets through its product offerings. TAM is estimated to be around $100 Billion USD.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Established brands (e.g., Bausch + Lomb)
- Strong presence in vision care and GI
- Global reach
Weaknesses
- High debt levels
- History of controversies and legal challenges
- Dependence on key products
- Generic competition
Opportunities
- New product development
- Emerging markets expansion
- Strategic acquisitions
- Increased demand for vision care and GI treatments
Threats
- Generic erosion
- Regulatory changes
- Competition from larger pharmaceutical companies
- Economic downturns
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- MRK
- ABBV
Competitive Landscape
Bausch Health competes with larger pharmaceutical and healthcare companies with greater financial resources. Its competitive advantages lie in its established brands and specialized product portfolio, but it faces challenges due to its debt and past controversies.
Major Acquisitions
Synergetics USA, Inc.
- Year: 2015
- Acquisition Price (USD millions): 192
- Strategic Rationale: Expanded Bausch + Lomb's surgical business.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been impacted by acquisitions, divestitures, and restructuring efforts. The company's focus has shifted from rapid expansion to debt reduction and operational efficiency.
Future Projections: Future growth projections depend on the company's ability to launch new products, manage its debt, and navigate regulatory challenges. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include divesting non-core assets, focusing on core business segments (Bausch + Lomb, Salix), and reducing debt.
Summary
Bausch Health is a diversified healthcare company focusing on vision care and GI health, but it carries significant debt. The Bausch + Lomb division remains a strong point. Managing debt and successfully launching new products are crucial for its future growth and competitive positioning, and resolving outstanding legal matters is a must.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market conditions and company performance can change rapidly. Consult a financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bausch Health Companies Inc
Exchange NYSE | Headquaters Laval, QC, Canada | ||
IPO Launch date 1994-03-29 | CEO & Director Mr. Thomas J. Appio | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 20700 | Website https://www.bauschhealth.com |
Full time employees 20700 | Website https://www.bauschhealth.com | ||
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.